MGNX MacroGenics Inc.

+0.5  (+3%)
Previous Close 18.24
Open 18.25
Price To Book 2.85
Market Cap 914617319
Shares 48,805,620
Volume 482,735
Short Ratio
Av. Daily Volume 834,718

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data due 2H 2019.
Phase 3 data released February 6, 2019 met primary endpoint. Detailed data due at ASCO June 4, 2019, 9:45am. BLA filing due 2H 2019.
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 2/3 trial to be initiated 2H 2019.
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 2 trial to be initiated 2H 2019.
Enoblituzumab and MGA012
Solid tumors
Phase 1 partial clinical hold lifted January 25, 2019.
Solid tumors
Phase 1 data due 2H 2019.
Solid tumors
Phase 1 trial initiated 4Q 2018.
Solid tumors

Latest News

  1. Is MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Overpaid Relative To Its Peers?
  2. Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
  3. Why MacroGenics, Inc. Stock Is Heating Up Today
  4. The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
  5. Microsoft, Amazon, and More: Why These Stocks Are Trending
  6. MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
  7. 3 Stocks With Big News Coming at ASCO 2019
  8. Edited Transcript of MGNX earnings conference call or presentation 26-Feb-19 9:30pm GMT
  9. Macrogenics Inc (MGNX) Q1 2019 Earnings Call Transcript
  10. MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
  11. MacroGenics: 1Q Earnings Snapshot
  12. MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
  13. Md. biotech files to go public in up to $92M offering
  14. MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call
  15. MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
  16. 3 Promising Small Biotech Stocks to Watch
  17. MacroGenics to Participate in Upcoming Investor Conferences
  18. Introducing MacroGenics (NASDAQ:MGNX), The Stock That Dropped 20% In The Last Five Years
  19. Why MacroGenics Stock Rocketed 70.5% Higher in February